DUBLIN--(BUSINESS WIRE)--The "Von Willebrand Disease (VWD) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
The total number of diagnosed prevalent population of Von Willebrand Disease (VWD) was found to be 35,396, in the year 2016.
Von Willebrand Disease (VWD) - Market Insights, Epidemiology and Market Forecast-2027 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of VWD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Von Willebrand Disease (VWD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
The Von Willebrand Disease (VWD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, sex-specific diagnosed prevalent cases, type specific diagnosed prevalent cases and age specific diagnosed prevalent cases) scenario of Von Willebrand Disease (VWD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
At present, there are broadly three therapeutic classes of drugs contributing towards the market size of VWD - Replacement Therapy, Non-Replacement Therapy and Adjunct/Supportive Therapy. The approved (and their generic versions) as well as off-label products that are being used for the treatment of Von Willebrand Disease, belong to either of these therapeutic classes only.
Detailed chapter for marketed therapies along with their regulatory details like Vonvendi (also known as BAX 111) (Shire), Wilfacin (LFB), Humate-P (CSL-Behring), Alphanate (Grifols Biological Inc), Immunate (Shire) and Voncento (CSL-Behring) have been covered in the report.
Key Topics Covered:
1. Key Insights
2. Von Willebrand Disease (VWD): Market Overview at a Glance
3. Disease Background and Overview: von Willebrand Disease (VWD)
4. Epidemiology and Patient Population
5. 7MM Total Diagnosed Prevalent Patient Population of von Willebrand Disease
6. Country Wise-Epidemiology of von Willebrand Disease
7. Treatment Algorithm, Current Treatment, and Medical Practices
8. Unmet Needs
9. Von Willebrand Disease: 7 Major Market Analysis
10. The United States Market Outlook
11. EU-5 Countries: Market Outlook
12. Market Drivers
13. Market Barriers
- CSL- Behring
- Octa Pharma
- Ferring Pharmaceuticals
- Grifols Biological Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/pn9dm3/von_willebrand?w=4